Start here if you're new
what it is
AMS puts hospital equipment and support around advanced brain and radiation treatments.
how it gets paid
Last year Ams made $28M in revenue. Gamma Knife financing and leases was the main engine at $16M, or 57% of sales.
what just happened
Revenue hit $20M, EPS was -$0.14, and gross margin stayed at 20.4%.
At a glance
C balance sheet — red flag territory — real financial stress
30/100 earnings predictability — expect surprises
1.1% return on capital — nothing to write home about
-$0.04 fy2024 eps est
$2B fy2026 rev est
xvary composite: 26/100 — weak
What they do
AMS puts hospital equipment and support around advanced brain and radiation treatments.
You are not buying a box. You are buying hospital setup. "Turnkey technology solutions" means equipment, financing, and setup so hospitals do not build it from scratch. AMS has Gamma Knife units in 10 U.S. centers and 2 Latin American sites, so your replacement cost is somebody else's downtime.
How they make money
$28M
annual revenue
Gamma Knife financing and leases
$16M
Radiation therapy services
$6M
Radiation equipment and CT simulator
$4M
Operating Room for the 21st Century and other services
$2M
The products that matter
flagship treatment platform
gamma knife radiosurgery
core niche asset
This looks like the mature base business. Segment revenue is not broken out in the snapshot, which matters because the whole company is valued at only about $14M. When disclosure is thin, you should default back to the debt math.
mature base
advanced treatment equipment
advanced radiation therapy
operating leverage watch
The prior Q3 report showed companywide revenue up 2.5% while EBITDA rose 42.3%. That gap is the appeal. A little more volume can move profit much faster when fixed costs are already sitting there.
42.3% EBITDA jump
what really drives the equity
capital structure repair
debt before upside
A 43% earnings beat helps sentiment. A December 2025 default notice on the revolving credit facility matters more. In a company this small, financing terms can overwhelm operating progress.
real catalyst
Key numbers
$28M
TTM revenue
A $14M market cap against $28M of sales means the stock trades at 0.5x revenue.
9.9%
operating margin
The business loses money after overhead, so revenue alone is not the fix.
$13M
long-term debt
Debt is 48% of capital, which is a lot for a $14M equity.
0.8
beta
Beta, or market bounceiness, is below 1.0. That is calmer than average, but it does not pay lenders.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 25 / 100
- long-term debt $13M (48% of capital)
C — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for AMS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $20M, EPS was -$0.14, and gross margin stayed at 20.4%.
The quarter was huge against a $28M full year. Revenue rose 184% from a year earlier, but profits stayed underwater.
$20M
revenue
$0.14
eps
20.4%
gross margin
quarter revenue
The $20M quarter mattered because it was 71% of full-year $28M revenue, which screams lumpy billing.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
AMS does not need a long list of theoretical risks. The page already gives you the main one: a December 2025 credit-facility default notice sits on top of a business with a C balance sheet, a -7.65% net margin, and only about $14M of market value.
med
credit facility default stays unresolved
This is the top risk. A default notice on the revolving credit facility was disclosed in December 2025. Until it is cured, waived, or refinanced, lenders matter more than quarter-to-quarter earnings optics.
This is the top risk. A default notice on the revolving credit facility was disclosed in December 2025. Until it is cured, waived, or refinanced, lenders matter more than quarter-to-quarter earnings optics.
med
operating improvement proves temporary
A -7.65% net margin means the business is still losing money. Revenue up 2.5% and EBITDA up 42.3% is encouraging, but one strong spread does not establish a durable trend.
A -7.65% net margin means the business is still losing money. Revenue up 2.5% and EBITDA up 42.3% is encouraging, but one strong spread does not establish a durable trend.
med
micro-cap trading turns the stock into a gap machine
A roughly $14M market cap and 25 / 100 price stability is a recipe for violent moves. Thin liquidity means small shifts in sentiment can move the stock more than fundamentals do.
A roughly $14M market cap and 25 / 100 price stability is a recipe for violent moves. Thin liquidity means small shifts in sentiment can move the stock more than fundamentals do.
This is a small business with real financing stress. If margins stay negative, the stock stays cheap for a reason.
source: institutional data · regulatory filings · risk analysis
Pay attention to
balance sheet
any update on the December 2025 default notice
This is still the first question. A waiver, cure, or refinancing would matter more than a small revenue beat because debt is $13M against a company worth about $14M.
earnings
can AMS keep EPS positive
The April 2, 2026 consensus EPS setup was $0.04 versus -$0.10 from a year earlier. You want positive earnings to become a pattern, not a cameo.
trend
does EBITDA keep growing faster than revenue
The prior Q3 report showed 2.5% revenue growth and 42.3% EBITDA growth. Same company. Very different slope. If that spread vanishes, so does much of the turnaround appeal.
trading setup
whether liquidity stays thin enough to overpower fundamentals
A $14M market cap and 25 / 100 price stability mean the stock can gap on very little volume. You are underwriting the business and the trading conditions.
Analyst rankings
earnings predictability
30 / 100
Low predictability means earnings are hard to model. In human-speak: expect surprises, both positive and negative.
balance sheet grade
C
This is a weak financial-health grade, not a cosmetic blemish. It matches the distress signals elsewhere on the page.
price stability
25 / 100
A 25 / 100 stability score usually means the stock will not behave politely. You should expect sharp moves and thin liquidity.
source: institutional data
Institutional activity
institutional ownership data for AMS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive